Ocular inflammatory diseases can present as isolated conditions but also as part of systemic inflammatory diseases. Anterior uveitis is closely related to SpA and shares the common genetic background of HLA-B27. Other ocular manifestations, such as episcleritis and scleritis, may also occur, although less frequently. Therefore, ocular involvement has been included as one of the important clinical features of SpA in the recently published classification criteria for axial and peripheral disease. However, there are a wide variety of aetiologies for ocular diseases and this must be considered in assessment of SpA.
Introduction
SpA is a heterogeneous group of diseases that includes AS, ReA, PsA, arthritis associated with IBD and uSpA. Although SpA is primarily a musculoskeletal condition, ocular involvement is an important clinical feature, since it is considered either a complication or an associated disease manifestation. The uvea is the layer of the eye that is most commonly affected. Uveitis in SpA is nongranulomatous and typically unilateral. Inflammatory involvement of adjacent layers of the eye, such as the retina or the corneoscleral shell, may also occur.
The terminology used to describe ocular involvement is still a matter of debate. Based on the anatomical borders, uveitis can be subdivided into anterior (if inflammation is located anteriorly to the lens) or posterior uveitis (defined as inflammation posterior to the lens). Another definition describes anterior and posterior uveitis as an inflammation of the iris (iritis) and the choroid area (choroiditis), respectively. In addition, inflammatory involvement of the ciliary body is named cyclitis, and panuveitis refers to when all three areas of the uvea are involved [1] . The International Uveitis Study Group states that uveitis should be classified according to location (anterior, intermediate, posterior and panuveitis), clinical course (acute, chronic and recurrent) and distribution (uni-or bilateral) [2] .
These classifications are useful tools for clinicians, especially because anterior uveitis is the most common form of uveitis and may precede other clinical features of SpA [3] . Undiagnosed SpA is common in patients with acute anterior uveitis (AAU), mainly in those that carry the HLA-B27 allele [4] . In a case series, up to 50% of patients who presented with AAU fulfilled the SpA classification criteria during follow-up [5] .
The association between AAU and HLA-B27 was first recognised in parallel to its description as a risk factor of AS [6, 7] . In the USA, about 50% of the patients with anterior uveitis have detectable HLA-B27 [8] . In daily practice, HLA-B27 determination is recommended in all patients who present with AAU, since it impacts diagnosis and prognosis.
Bañ ares et al. classified uveitis in different clinical patterns (anatomical location, clinical course, distribution) and tried to correlate them with the underlying aetiology. In this series of 407 patients, SpA was the most frequent diagnosis found in the subset of acute recurrent unilateral anterior uveitis (48.2%; n = 139) [9] . Of note, some SpA patients with acute non-recurrent unilateral anterior uveitis were probably misdiagnosed as idiopathic, due to the lack of sensitivity of the former classification criteria for SpA applied and to the absence of MRI studies.
In a German specialized centre, 1916 patients with inflammatory eye disease were evaluated, and anterior uveitis was the most common presentation (45.4%). Considering only those with uveal inflammation (anterior, intermediate, posterior and panuveitis), 62.4% (1052 patients; n = 1686) had a specific diagnosis. Of these, 41.8% had an associated systemic disease, AS and sarcoidosis being the most frequent diagnosis. In the group of ocular syndromes, the most frequent disease was HLA-B27-associated AAU (HLA-B27 AAU), occurring in 35% of cases [10] . It is noteworthy that, after publication of the Assessment of SpondyloArthritis international Society (ASAS) classification criteria [11] , HLA-B27 AAU was included as a clinical feature of SpA. In this study, there was a 9.5% probability of AS in AAU patients. Nonetheless, when alternating laterality, male sex or adult age was present, this risk increased to 40.1% [10] .
Although AAU is closely related to SpA, there are no formal guidelines to refer these patients to a rheumatologist for evaluation. In a retrospective study, although 73% of AAU patients with HLA-B27 showed rheumatological manifestations, only half of them were referred to a rheumatologist for further diagnostic clarification [12] . The Dublin Uveitis Evaluation Tool was therefore published in an effort to diagnose SpA earlier in patients with AAU. This study shows the importance of HLA-B27 determination when a uveitis patient is admitted. In cases of clinical symptoms such as chronic inflammatory back pain, peripheral arthritis or psoriasis, especially in the presence of HLA-B27, these patients should be referred to a rheumatologist, since about half of them may also have SpA or ReA [13, 14] .
A recent study assessed the ability of the Berlin Criteria for inflammatory back pain to find undiagnosed SpA in a population of AAU. It was suggested that instead of fulfilling two positive criteria, those AAU patients that fulfil only one should be considered as having a high probability of having SpA [15] .
The aim of this paper is to review the most relevant aspects of ocular manifestations of SpA, especially AAU. Epidemiology AAU is classically described as the most common extraarticular manifestation in SpA. However, the prevalence of AAU varies among these patients. In a systematic literature review, the mean prevalence was 32.7%, but it varied according to the type of SpA. AS is considered to be the disease with the highest prevalence of AAU (33.2%), and such manifestations are less common in ReA and PsA. The data for the prevalence of uveitis in arthritis associated with IBD were based on only three articles and need to be confirmed in larger cohorts. A negative relationship was found between skin disease (psoriasis) and the presence of AAU. Uveitis in PsA patients is considered to be less common than in other forms of SpA (25.1%) [16] .
More recently, a multicentric Ibero-American cohort study found AAU in almost 20% of the patients with SpA, reinforcing the evidence that this is the most common extra-articular manifestation of SpA. AAU was associated with axial disease and HLA-B27 positivity. PsA was also negatively associated with AAU in this study [17] . In another study, the prevalence of AAU was 40% in AS patients (n = 1331), and almost half of them had >5 attacks [18] . Rudwaleit et al. [19] compared patients with non-radiographic axial SpA and AS and did not find statistically significant differences in the prevalence of AAU, although there was a trend toward a lower frequency of uveitis in the former group.
The prevalence of SpA in the AAU population varies in different cohorts, due to regional and genetic differences and also to the heterogeneous classification criteria used in each study. Considering only HLA-B27-associated AAU, a retrospective Chinese study with 240 patients identified 124 patients that fulfilled SpA criteria (51.7%); among them, 45% were diagnosed with AS [20] . In another study, the prevalence of SpA was 76.8% among 504 Chinese patients with HLA-B27-associated AAU (a total of 1719 attacks). Association with SpA was related with an earlier age of uveitis onset and with a higher number of uveitis attacks [21] . Monnet et al. [22] also found that 78% of HLA-B27-related AAU patients had extra-ocular disease, almost always AS (46.3%). Musculoskeletal symptoms preceded the first episode of AAU in > 80% of the cases.
Linder et al. used the European SpA Study Group criteria to determine the frequency of various types of SpA in patients with uveitis (acute anterior uveitis, chronic anterior uveitis, posterior uveitis, panuveitis). SpA was observed in 36/93 (39%) AAU patients, and this was the most frequent type of uveitis in SpA patients [23] .
Smith et al. have shown that male patients are more prone to develop SpA-associated AAU, at an earlier age of onset. Women tend to develop a less classic form of HLA-B27 AAU, with more insidious onset and a recurrent course. However, rates of complication and visual loss were not influenced by gender [24] .
Genetics
The association between AAU and HLA-B27 was first demonstrated in the early 1970s [6, 7] . AAU is significantly more common in HLA-B27-positive AS patients. In this cases, the prevalence of AAU is around 30%, in contrast with only 10% if HLA-B27 is absent. The risk increases to 35% if, in addition to HLA-B27, HLA-A2 is simultaneously present. Nevertheless, an independent association of AAU with HLA-A2 has not been shown so far [25] .
Other MHC-linked genetic factors are also being associated with susceptibility to AAU in AS patients. In a Japanese population, Monowarul et al. [26] have shown that patients who presented with AAU also tested positive for HLA-DR8 (65 vs 4.5% without AAU, P < 0.001), suggesting that HLA-DR8 may also play a role in the www.rheumatology.oxfordjournals.org development of AAU. Linssen et al. [27] analysed the occurrence of symptoms of eye redness in 539 healthy patients during 10 years of follow-up, and showed a lifetime cumulative incidence of definite AAU of 0.2% in the general population and 1% in the HLA-B27 population. The higher risk of uveitis in SpA patients with HLA-B27 [odds ratio (OR) = 4.2 (95% CI: 3.3, 5.3)] [16] confirms the association between genetic and ophthalmological disease suggested in previous studies [2831] .
In a large Chinese study, with 846 AS patients and 959 healthy controls, the correlation between HLA-B27 polymorphism and the clinical features of AS were investigated. In total, HLA-B27 was found in 87.6% of AS patients and 4% of controls, being HLA-B*2704 (88%) and HLA-B*2705 (10.1%), the most prevalent subtypes in AS. Those with HLA-B*2705 were more prone to develop uveitis (16 vs 6.13%, P = 0.002) and dactylitis (9.3 vs 3.8%, P = 0.028), with an older age of symptom onset There were no significant differences in any relevant clinical symptoms among HLA-B27 subtypes [32] .
Another Chinese study reported that >90% of of the Chinese AS patients display the HLA-B27 antigen with the predominance of the HLA-B*2704 subtype. They have higher frequencies of juvenile-onset AS, peripheral arthritis, earlier disease onset and more recurrent attacks of HLA-B27-related AAU [33] . Polymorphisms in the IL-23R gene are probably also implied in the pathogenesis of AAU in SpA patients, since it occurs in patients with AS and AAU [34] .
In spite of the results from a previous study, which did not find either significant differences in phenotype MZ of alpha-1 antitrypsin (a 1 -AT)/alpha-1 protease inhibitor between different groups of the patients and healthy controls, or between patients with AAU alone and patients with AAU and systemic diseases, others documented different results [35] . Fearnley and colleagues reported an increased incidence of the a 1 -AT phenotype PiMZ in patients with AAU, indicating an important role in the immunogenetics of this condition. a 1 -AT-PiMZ was found to occur in 6% of patients with AAU (vs 2.6% in normal population), with the highest incidence (9%) in patients negative for HLA-B27 and without sacroiliac joint disease. Severity and bilateral occurrence or recurrence of AAU were similar between groups. Despite the increased incidence of this phenotype, its clinical relevance is not fully understood; the most likely explanation is possible association with other immunoregulatory genes [36] .
Raised levels of IgAa 1 -AT complexes were associated with active disease, ESR, CRP and serum IgA in a study with 61 patients with AS. This association was noted especially in patients reporting 'extraspinal' manifestations, including uveitis [37] . In addition, serum prolactin levels have also been found to correlate with HLA-B27 AAU. In a recent prospective trial, prolactinaemia was significantly higher in patients with HLA-B27-negative uveitis, particularly in those who had arthritis. Prolactinaemia did not correlate with disease activity [38] .
Clinical features and prognosis
SpA can affect different eye structures, including the esclera, episclera and the uveal tract. Anterior uveitis is the most common manifestation, as mentioned above. We will focus the discussion on this latter manifestation.
Acute anterior uveitis
Anterior uveitis can be presented with an acute, chronic or recurrent course. In SpA patients, it is characteristically described as a unilateral recurrent AAU. Blurred vision is probably the most common symptom, due to the turbidity of the aqueous layer. Pain, circumlimbal redness and watering may also occur. Photophobia is caused by ciliary muscle spasm (also responsible for pain), associated with anterior chamber cellular inflammation, corneal epithelium oedema and pupillary muscle involvement [39] .
An ophthalmological evaluation is of the utmost importance, and both anterior and posterior segments should be checked. Circumcorneal congestion occurs due to dilation of episcleral vessels. Keratic precipitates, which represent cell deposits in the corneal endothelium, help to differentiate granulomatous (large precipitates) from nongranulomatous uveitis (fine precipitates- Fig. 1 ). Coloured or pigmented keratic precipitates may be found in patients who had previous AAU flares. Identification of aqueous cells, representing inflammatory cells in the anterior chambers, is the most specific sign of active inflammation and may be found early; aqueous flares are an indirect sign of active uveitis. Both, when present, should be graded in order to assess response to therapy. Hypopyon, pupillary membrane (Fig. 2) and hyphema (blood cells in the anterior chamber) are also described. In the iris examination, myosis can be present, due to sphincter reflex spasm. Posterior synechiae (Fig. 3) are adhesions between the lens and the iris that occur after recurrent episodes of uveitis, and may precipitate secondary glaucoma. Cataract and iris atrophy may also arise as complications [39] .
Although a previous report assessed an equal ocular outcome of 119 AAU patients with HLA-B27 compared with 35 without after a mean follow-up of 9 years [40] , HLA-B27-related AAU is considered a distinct disease. It was described as having an earlier onset and unilateral involvement [41] , and with an increased chance of relapse and developing lower visual acuity [20] , when compared with patients that were HLA-B27 negative.
A review of 148 records of HLA-B27-positive patients with uveitis was performed with the aim of describing their clinical characteristics. The unilateral or unilateral alternating ocular involvement was the most common presentation in 93% of the patients, as well as AAU in 87% [4] . A comparison between two groups of patients with recurrent AAU (60 HLA-B27-positive patients vs 105 HLA-B27-negative patients) was performed in an Italian population. The HLA-B27-positive group was more prone to present systemic diseases (P < 0.001) and had a higher unilateral involvement (P = 0.046) when compared with the other group [3] .
Regarding only patients with AS, uveitis was confirmed as the most common extra-articular manifestation and was associated to disease duration in a systematic review and a meta-analysis that were recently published [42] . However, there was a large heterogeneity among studies that can be influenced by differences in clinical and methodological characteristics [42] . A retrospective cohort studied 364 eyes from 285 patients with uveitis (313 anterior uveitis, 36 intermediate uveitis or 15 panuveitis) admitted in a Canadian referral centre. HLA-B27 AAU was found in 23.6% of the patients. AS (11.3%), IBD (6%), sarcoidosis (4.1%) and herpes infections (3.8%) were the most common associations. Recurrence was more frequent in patients with complicated uveitis and axial involvement (OR = 3.86 and 2.29) [43] .
Ji et al. retrospectively evaluated 233 Chinese patients (male/female ratio of 10:1) with uveitis associated with AS. They found that HLA-B27 antigen was presented in 82.5%, and unilateral and bilateral involvement occurred in 55.2% and 45.3%, respectively. In general, the prognosis is good in these cases, improving with a combination of corticosteroids and other mydriasis agents [44] .
Other diseases that are associated with SpA, such as IBD, have also been reported to be significantly increased in the HLA-B27 AAU patients, as compared with the HLA-B27-negative AAU patients. In this study, HLA-B27 AAU male patients showed an increased occurrence of urogenital infections [45] . Seventeen patients with uveitis and IBD had their features compared with 89 patients with uveitis and SpA. Those patients with IBD frequently had uveitis that was bilateral, posterior, insidious in onset and/or chronic in duration. Episcleritis, scleritis and glaucoma were more common among them. In more than half (59%) of the patients with IBD, uveitis was diagnosed prior to IBD [46] . In PsA, uveitis also tends to be more insidious in onset, chronic, posterior and active bilaterally, when compared with other SpA [4749] .
Other ocular manifestations of SpA
While the AAU is closely related to SpA and was included in the ASAS classification criteria for axial and peripheral disease, the posterior uveitis is rarely associated with the presence of HLA-B27 alleles. It usually occurs as the residual of a severe episode of anterior and posterior uveitis. Choroiditis is not a feature of the uveitis associated with either AS or ReA (Xenofon Baraliakos, author's communication).
Scleritis and episcleritis are ocular findings described in SpA, but their incidences are far less than that of uveitis. The SpA have each been associated, in varying degrees, with scleritis and episcleritis. The vast majority of occurrences of episcleritis have no systemic association, and the course of the disease is benign and self-limiting. Scleritis has a greater association with systemic disease. Although the most common rheumatological correlation with scleritis is RA, other disease associations include the SAs. In a recent retrospective study, patients with SAs made up 5.8% of all those with scleritis seen at a tertiary referral centre. This percentage included IBD (3.3%), AS (1.3%), ReA (0.8%) and PsA (0.4%) [50] . It is important to differentiate between scleritis and episcleritis because the treatment, prognosis and systemic associations differ markedly for these two diseases.
Treatment
Patients with AAU tend to improve with topical corticosteroid treatment, and systemic drugs are usually not indicated in these cases. Indeed, this presentation is the most easily managed form of uveitis. However, depending on the number of recurrences of attacks, it may complicate with synechiae, glaucoma, or cystoid macular oedema and may also result in visual loss. In this way, some drugs are available for the management of recurrent AAU including NSAIDs, corticosteroids, immunomodulatory agents and, more recently, anti-TNF therapy.
Fiorelli et al. showed that NSAIDs were able to reduce AAU flares in patients with recurrent, non-granulomatous, idiopathic or HLA-B27-related AAU. The relapse rate after using celecoxib or diflunisal was 0.53 per person-year (vs 2.84 per person-year prior to treatment, P < 0.001) [51] . Trials with SpA-associated AAU are needed to confirm these findings.
Regarding the use of immunomodulatory drugs, SSZ and MTX were the most studied. Benitez-Del-Castillo et al. [52] published a randomized, prospective, open study of 22 patients with AS (10 treated with the drug studied and 12 with no treatment) and demonstrated that SSZ may prevent recurrences and reduce the severity of AU associated with AS in 3 years of follow-up. Another group published a not controlled, prospective, open study that evaluated 10 patients (four patients with AS) with recurrent uveitis during 1 year of follow-up. These results support the data previously described [53] . Different authors have used MTX in the treatment of non-infectious inflammatory eye disease, with good outcomes. Nonetheless, many of them were non-randomized retrospective studies and included different ocular diseases in their analysis [5456] .
Samson et al. restrospectively evaluated the effectiveness of MTX in 160 patients with chronic non-infectious uveitis refractory to steroid therapy. Of these, 104 (65%) presented with anterior uveitis, 37 patients were HLA-B27 positive and nine were previously diagnosed with SpA. MTX was initiated at 7.5 mg/week and the dose was increased 2.55 mg every 6 weeks, until clinical response or intolerance. The rate of response was 81.4% for anterior uveitis and 73% for HLA-B27-positive patients. The authors concluded that MTX was effective and safe in patients that fail to response to conventional steroid therapy [57] . Another study enrolled nine patients with recurrent AAU (three or more episodes), but only one with SpA. MTX reduced the number of recurrences from 3.4 ± 0.52 to 0.89 ± 1.17 (P = 0.001) in the year of treatment [58] . These studies suggest that MTX may be effective in the treatment of refractory or recurrent AAU, but larger randomized trials are needed to confirm these findings.
The use of anti-TNF therapy as an adjuvant in the treatment of refractory uveitis has been reported [59] , but some data suggested these biologic agents may have different performances in preventing these episodes. A meta-analysis of seven clinical trials, four of which were placebo-controlled, randomized trials, demonstrated a significant difference between placebo and anti-TNF therapy (P = 0.01) in the incidence of AU flares in AS patients. The anti-TNF mAb infliximab (P = 0.005) appeared to be more effective than the receptor antagonist etanercept (P = 0.05) therapy when they were compared with placebo, but there was no statistically significant difference between these anti-TNF agents (P = 0.08), while adalimumab was not evaluated in this study [60] . The effect of adalimumab on the frequency of AU flares in patients with active AS was determined in a multinational, open-label, uncontrolled clinical study that evaluated uveitis as a secondary outcome. It was described as a 50% reduction of the incidence of uveitis in all patients, but it reached 68% of reduction in those with a recent history of AU. Most flares that occurred during the treatment were mild. It must be stressed that even patients with an improvement in their clinical disease must be followed by an experienced ophthalmologist, because most AU flares occurred in patients with good clinical response [61] . Recently, adalimumab received US Food and Drug Administration approval for treating non-infectious intermediate, posterior and panuveitis, but not acute anterior uveitis. The pivotal clinical trials used an 80 mg baseline loading dose, followed by 40 mg at week 1 and then 40 mg every other week [62, 63] . A large retrospective study suggested that both infliximab and adalimumab reduced the rate of AU flares, while etanercept did not [64] . However, eight clinical trials of etanercept (four of which were placebo-controlled) in AS were examined for reports of uveitis. In this study, rates of uveitis were lower in patients treated with etanercept, when compared with placebo in controlled trials [65] .
Although anti-TNF antagonist is indicated to prevent uveitis, there were anecdotal reports that implicate etanercept as a cause of it. In this setting, a retrospective study based on a drug events database was conducted. Lim et al. found a greater number of uveitis cases in the etanercept group, when compared with infliximab (P < 0.001) and adalimumab (P < 0.01). The results were consistent with previous studies, suggesting a specific drug effect, and not with all anti-TNF agents [66] .
Another study based on spontaneous case reports was conducted in France with the aim to document the cases of new onset of uveitis under anti-TNF treatment. Six patients (19.3%) had a diagnosis of RA, and 19 (61.3%) had a diagnosis of AS. As RA is not associated with uveitis, if the diagnosis of RA is correct, these cases could be related to the use of anti-TNF therapy [67] . A possible differential diagnosis in a patient already on anti-TNF therapy that complains of ocular symptoms is the infliximabinduced demyelination, which has been previously described [68] .
Conclusions
AAU is closely related to SpA and has been included in the ASAS classification criteria for axial and peripheral disease. There is a mean prevalence of 33%, but it varied according to the type of SpA. On the other hand, the diagnosis of SpA is more prevalent among patients with AAU, and the ophthalmological complaint could be the first presentation of these patients. Yet, it must be stressed that there are a variety of other aetiologies of red eyes in the differential diagnosis and it is important to promptly treat them. Multi-professional teams are important for early diagnosis, to prevent a visual loss.
Funding: No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the work described in this manuscript.
Disclosure statement: R.A.L. has received honoraria, been a consultant to and received speaker fees from AbbVie, Janssen, Pfizer, Roche and UCB. All other authors have declared no conflicts of interest.
